#Japan #Tokyo #Drug Discovery #PRISM BioLab #Talus Bioscience

PRISM BioLab and Talus Bioscience Collaborate on Drug Discovery

In a significant collaboration announced in December 2025, PRISM BioLab, Co. Ltd. and Talus Bioscience, Inc. have embarked on a groundbreaking project aimed at discovering novel inhibitors for transcription factors (TF) and protein-protein interactions (PPI). This partnership promises to revolutionize the field of drug discovery by combining advanced assay technologies and proprietary chemical libraries.

Under the terms of the agreement, PRISM will utilize its proprietary small-molecule libraries alongside Talus Bio's innovative AI-guided regulome profiling screens. This strategic collaboration is expected to identify and optimize new compounds that exhibit direct functional effects on the activity of TFs and PPIs in living human cells. By harnessing the synergies of both companies, they aim to create first-in-class chemical entities that could pave the way for novel therapeutics targeting diseases considered previously difficult to approach.

Dai Takehara, President and CEO of PRISM, expressed enthusiasm about the collaboration. He noted that while PRISM has made strides in developing chemistries for PPI targets, the complexity of these interactions has often hampered successful modeling in traditional biochemical assays. In contrast, Talus Bio’s technology allows for large-scale assessment of multiple targets concurrently, providing the unique capability to interrogate the cellular environment where these interactions occur.

The potential for this collaboration is immense, particularly in its ability to explore previously